Financial Ratios

JB CHEMICALS & PHARMACEUTICALS LTD.

NSE : JBCHEPHARMBSE : 506943ISIN CODE : INE572A01036Industry : Pharmaceuticals & DrugsHouse : Private
BSE1649.453.45 (+0.21 %)
PREV CLOSE ( ) 1646.00
OPEN PRICE ( ) 1622.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4997
TODAY'S LOW / HIGH ( )1622.05 1690.00
52 WK LOW / HIGH ( )914.65 1935
NSE1650.407.5 (+0.46 %)
PREV CLOSE( ) 1642.90
OPEN PRICE ( ) 1651.15
BID PRICE (QTY) 1650.40 (545)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 147335
TODAY'S LOW / HIGH( ) 1643.45 1694.70
52 WK LOW / HIGH ( )875 1940
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)50.2646.7157.8534.7022.69
   CEPS(Rs)32.3727.9733.2821.5614.76
   DPS(Rs)17.7516.5016.5011.005.00
   Book NAV/Share(Rs)299.94264.10233.75187.02185.02
   Tax Rate(%)26.2123.4024.7021.0332.39
Margin Ratios
   Core EBITDA Margin(%)22.2222.7029.1922.4419.21
   EBIT Margin(%)18.7621.2531.7620.8918.24
   Pre Tax Margin(%)17.6221.0331.3820.7017.94
   PAT Margin (%)13.0016.1123.6316.3412.13
   Cash Profit Margin (%)16.7419.2927.1920.3115.78
Performance Ratios
   ROA(%)11.0913.0419.6512.367.99
   ROE(%)17.8318.7727.5018.3012.39
   ROCE(%)22.0224.0436.3322.9618.30
   Asset Turnover(x)0.850.810.830.760.66
   Sales/Fixed Asset(x)1.391.541.711.551.51
   Working Capital/Sales(x)3.362.861.642.301.98
Efficiency Ratios
   Fixed Capital/Sales(x)0.720.650.580.650.66
   Receivable days63.5472.6469.2971.6472.99
   Inventory Days44.9451.1949.2948.9646.67
   Payable days73.5788.4192.1384.4071.98
Valuation Parameters
   PER(x)39.2233.7221.6714.6515.85
   PCE(x)30.4528.1618.8311.7912.18
   Price/Book(x)6.575.965.362.721.94
   Yield(%)0.901.051.322.161.39
   EV/Net Sales(x)5.455.555.122.411.93
   EV/Core EBITDA(x)23.3522.2114.509.458.79
   EV/EBIT(x)28.0125.5316.1211.5210.55
   EV/CE(x)3.924.063.821.961.24
   M Cap / Sales5.295.565.122.391.92
Growth Ratio
   Net Sales Growth(%)31.7015.7415.319.3019.62
   Core EBITDA Growth(%)22.98-18.0759.9427.1237.86
   EBIT Growth(%)17.87-20.7575.3325.1550.09
   PAT Growth(%)7.72-19.2566.7347.2842.23
   EPS Growth(%)7.59-19.2566.7352.9148.14
Financial Stability Ratios
   Total Debt/Equity(x)0.230.010.010.020.02
   Current Ratio(x)2.542.872.782.441.99
   Quick Ratio(x)1.872.042.351.971.72
   Interest Cover(x)16.3696.2483.55108.3459.98
   Total Debt/Mcap(x)0.030.000.000.010.01

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.